Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers

Share :
Sorry, this item is currently unavailable.
Published: 26 Oct 2016
Views: 2486
Dr Sibylle Loibl - German Breast Cancer Group

Dr Loibl discusses current indications for CDK 4/6 inhibitors (plus antiestrogen) as well as possible biomarkers at the 'Coming of Age for CDK 4/6 Inhibitors' symposium at ESMO 2016.

Her presentation is followed by a question and answers session.

Supported by a grant from Pfizer Inc.